This November 2001 Chartbook updates data from last year’s chartbook, including information about prescription drug coverage, expenditures and prices, utilization, drug promotion, and the pharmaceutical industry.
Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
Featured Prescription Drugs Resources
With increased national attention towards prescription drug costs, this poll examines the public’s experiences with prescription medicine and their views on current policy proposals brought forth by congressional lawmakers and the Trump administration, including international reference pricing, transparency in drug advertisements, and negotiations with drug companies. The survey also dives into the attitudes and experiences of adults, 65 and older – a group that is more likely to report taking prescription medication and shopped for prescription drug coverage.
Poll Finding See More
Related Prescription Drugs Resources
- What are the recent and forecasted trends in prescription drug spending?
- Kaiser Health News Coverage of Prescription Drug Issues
- 10 Things to Know About Medicare Part D Coverage and Costs in 2019
- Medicaid’s Prescription Drug Benefit: Key Facts
- Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs
- How Much Does Medicare Spend on Insulin?
- How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid?
- What’s in the Administration’s 5-Part Plan for Medicare Part D and What Would it Mean for Beneficiaries and Program Savings?
- Public Opinion on Prescription Drugs and Their Prices
- What Are Recent Trends and Characteristics of Workers with High Drug Spending?
- Closing the Medicare Part D Coverage Gap: Trends, Recent Changes, and What’s Ahead
- Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
- 10 Essential Facts About Medicare and Prescription Drug Spending
- Searching for Savings in Medicare Drug Price Negotiations
- Retail Prescription Drugs Filled at Pharmacies per Capita
How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?
Prescription drug costs are a pressing concern for both consumers and policymakers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which does not account for rebates.
Issue Brief See More
- view as grid
- view as list
Health News Index July/August, 2001 The July/August 2001 edition of the Kaiser Family Foundation/Harvard School of Public Health, Health News Index includes questions about major health stories covered in the news, including stem cell research and patients rights legislation. The Health News Index is designed to help the news media…
Summary Report This report, : Summary Report, produced jointly by the bipartisan team of Bill McInturff of Public Opinion Strategies and Geoff Garin of Peter D. Hart Research Associates, presents key findings from a series of eight focus groups on the Medicare program and the current debate over prescription drug…
Health News Index May/June, 2001 The May/June 2001 edition of the Health News Index includes questions about major health stories covered in the news, including the Supreme Court ruling regarding the distribution of medical marijuana and the debate in Congress over a Patients Bill of Rights. This edition also includes…
This report, written by Marilyn Moon and Matthew Storeygard of the Urban Institute, estimates the potential cost of targeting drug benefits to low-income Medicare beneficiaries and those with catastrophic drug expenses and discusses some of the key programmatic issues that could arise under this approach. The authors predict that a…
Tricia Neuman, Vice President and Director of the Medicare Policy Project, testified before the Senate Finance Committee on prescription drug coverage under Medicare. The statement reviews existing sources of prescription drug coverage for Medicare beneficiaries and the importance of such coverage for this population. It reviews current approaches for improving…
National ADAP Monitoring Project Report This report, the fifth in an annual series, provides an overview of the status of state-administered AIDS Drug Assistance Programs (ADAPs) and documents how these programs are responding to the changing fiscal, clinical and epidemiological dynamics of HIV/AIDS. ADAPs, authorized under Title II of the…
Diane Rowland, executive director of the Commission, testified to the Subcommittee on Health of the U.S. House Committee on Energy and Commerce about providing prescription drugs to seniors. Her testimony includes discussion of Medicaid's role in providing outpatient drug coverage.Testimony Chart Pack
Gynecological services are vital for women throughout their lifetimes. Pap smears, breast exams, counseling, and contraceptive care are important preventive services, but women often do not get these at levels recommended by experts. This fact sheet summarizes coverage of gynecological care and contraceptives. It focuses on women’s use of services,…
This background paper discusses the coverage of prescription drugs through the Medicaid program. Some of the issues addressed include who is eligible to receive drugs, how drug coverage is paid for, and how much money states spend on drugs.Background Paper